These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 6104720)

  • 21. An economical screen for phenethylamine-type hallucinogens: mouse ear scratching.
    Yim GK; Prah TE; Pfister WR; Nichols DE
    Commun Psychopharmacol; 1979; 3(3):173-8. PubMed ID: 574070
    [No Abstract]   [Full Text] [Related]  

  • 22. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
    Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
    J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents.
    Glennon RA; Rosecrans JA; Young R
    Med Res Rev; 1983; 3(3):289-340. PubMed ID: 6350763
    [No Abstract]   [Full Text] [Related]  

  • 24. Psychotomimetic drugs: biochemistry and pharmacology.
    Brimblecombe RW
    Adv Drug Res; 1973; 7():165-206. PubMed ID: 4613150
    [No Abstract]   [Full Text] [Related]  

  • 25. Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures.
    Appel JB; White FJ; Holohean AM
    Neurosci Biobehav Rev; 1982; 6(4):529-36. PubMed ID: 7177512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hallucinogens and Drosophila: linking serotonin receptor activation to behavior.
    Nichols CD; Ronesi J; Pratt W; Sanders-Bush E
    Neuroscience; 2002; 115(3):979-84. PubMed ID: 12435434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors.
    Westkaemper RB; Glennon RA
    NIDA Res Monogr; 1994; 146():263-83. PubMed ID: 8742803
    [No Abstract]   [Full Text] [Related]  

  • 28. Differential antagonism by metergoline of the behavioral effects of indolealkylamine and phenethylamine hallucinogens in the rat.
    Commissaris RL; Lyness WH; Moore KE; Rech RH
    J Pharmacol Exp Ther; 1981 Oct; 219(1):170-4. PubMed ID: 6793709
    [No Abstract]   [Full Text] [Related]  

  • 29. Potentiation of bufotenine-like syndrome induced by diethyltryptamine in reserpinized rats.
    Khazan N; Hirsch A; Sulman FG
    Electroencephalogr Clin Neurophysiol; 1967 Jun; 22(6):589. PubMed ID: 4165027
    [No Abstract]   [Full Text] [Related]  

  • 30. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent.
    Nichols DE; Monte A; Huang X; Marona-Lewicka D
    Behav Brain Res; 1996; 73(1-2):117-9. PubMed ID: 8788487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of LSD25 and Deseril on the behaviour and level of biogenic amines in a rat's brain (author's transl)].
    Kleinrok Z; Jagiełło-Wójtowicz E; Borzecki Z
    Ann Univ Mariae Curie Sklodowska Med; 1976; 31():147-54. PubMed ID: 802166
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effects of D-lysergic acid diethylamide (LSD-25) and 2-bromo-D-lysergic acid diethylamide (BOL-148) on sleeping behavior in rats].
    Loew DM; Depoortere H; Vigouret JM
    Naunyn Schmiedebergs Arch Pharmakol; 1970; 266(4):394-5. PubMed ID: 4326420
    [No Abstract]   [Full Text] [Related]  

  • 33. LSD and phenethylamine hallucinogens: new structural analogy and implications for receptor geometry.
    Nichols DE; Pfister WR; Yim GK
    Life Sci; 1978 Jun; 22(24):2165-70. PubMed ID: 672453
    [No Abstract]   [Full Text] [Related]  

  • 34. Structure-activity relationships in potentially hallucinogenic N,N-dialkyltryptamines substituted in the benzene moiety.
    Kline TB; Benington F; Morin RD; Beaton JM
    J Med Chem; 1982 Aug; 25(8):908-13. PubMed ID: 7120280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hallucinogen caused motility disorders in rats as potential psychosis relevant animal model].
    Oelssner W
    Samml Zwangl Abh Geb Psychiatr Neurol; 1982; 50():53-60. PubMed ID: 7157125
    [No Abstract]   [Full Text] [Related]  

  • 36. Lysergic acid diethylamide induces behavioral changes in Caenorhabditis elegans.
    Ornelas IM; Carrilho BS; Ventura MAVC; Domith I; de V Silveira CM; Dos Santos VF; Delou JM; Moll F; Pereira HMG; Junqueira M; Aguilaniu H; Rehen S
    Neurosci Lett; 2024 Aug; 837():137903. PubMed ID: 39025433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonergic properties of beta-phenethylamine in rats.
    Sloviter RS; Connor JD; Drust EG
    Neuropharmacology; 1980 Nov; 19(11):1071-4. PubMed ID: 6449675
    [No Abstract]   [Full Text] [Related]  

  • 38. Lysergamides revisited.
    Pfaff RC; Huang X; Marona-Lewicka D; Oberlender R; Nichols DE
    NIDA Res Monogr; 1994; 146():52-73. PubMed ID: 8742794
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of drug discrimination procedures to characterize hallucinogenic drug actions.
    Appel JB; Cunningham KA
    Psychopharmacol Bull; 1986; 22(3):959-67. PubMed ID: 3797596
    [No Abstract]   [Full Text] [Related]  

  • 40. Neurotransmitter basis of the behavioral effects of hallucinogens.
    Rech RH; Commissaris RL
    Neurosci Biobehav Rev; 1982; 6(4):521-7. PubMed ID: 6817241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.